| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $20,391,154 ) (Continued on the next page) |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA288808 | Epigenetic Regulation of T Cell Metabolism and Immune Functions by Sirt6 | 000 | 1 | NIH | 12/18/2024 | $219,491 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 000 | 4 | NIH | 12/6/2024 | $2,697,909 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R35NS137447 | Expanding insights into FTD disease mechanisms | 000 | 1 | NIH | 12/6/2024 | $1,138,538 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG074879 | Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations | 002 | 3 | NIH | 3/25/2025 | $8,409,935 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R37CA248298 | Role of Sirt2 in T Cell Metabolism | 002 | 6 | NIH | 2/14/2025 | $322,194 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 001 | 5 | NIH | 2/14/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG076537 | Extracellular vesicle-based senotherapeutics for aging diabetic kidneydisease | 000 | 3 | NIH | 3/24/2025 | $521,046 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA262393 | Targeted Prevention of Postpartum-Related Breast Cancer (PRBC) | 000 | 4 | NIH | 3/6/2025 | $585,271 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077656 | Accelerated Resolution Therapy for Early Maladaptive Grief: A Clinical Trial | 000 | 3 | NIH | 3/6/2025 | $592,775 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG087165 | Elucidating the Pathomechanisms of APOE4 in Lewy Body Dementia | 000 | 2 | NIH | 3/14/2025 | $699,413 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG074879 | Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations | 003 | 3 | NIH | 4/1/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG071226 | Endothelial cell senescence and APOE4 in vascular cognitive impairment and dementia | 001 | 3 | NIH | 3/17/2025 | $352,125 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01GM144393 | Exploiting new approaches for selective inhibition of trypsins | 000 | 4 | NIH | 11/14/2024 | $263,805 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA295558 | Generating Synthetic Lethality in Glioblastoma with a First-In-Class Non-Muscle Myosin II Inhibitor | 000 | 1 | NIH | 12/25/2024 | $607,634 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG079859 | Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimer’s disease | 000 | 3 | NIH | 1/28/2025 | $492,975 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 000 | 5 | NIH | 1/22/2025 | $290,242 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA279916 | Deiminated molecules as markers for developing pancreatic cancer - A1 | 000 | 2 | NIH | 11/15/2024 | $197,542 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 000 | 2 | NIH | 11/15/2024 | $49,174 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA296671 | ECT2 Isoform Switch in Pancreatic Cancer. | 000 | 1 | NIH | 11/21/2024 | $219,491 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS129671 | Tumor targeted drug delivery nanoplatform to overcome therapy resistance glioblastoma | 000 | 3 | NIH | 12/13/2024 | $556,541 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077771 | Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS | 000 | 3 | NIH | 11/19/2024 | $648,262 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01NS119169 | Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial | 000 | 4 | NIH | 12/31/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U24CA277825 | The Data, Evaluation, and Coordination Center (DECC) for Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) | 001 | 4 | NIH | 12/11/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG074879 | Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations | 000 | 2 | NIH | 10/17/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG074879 | Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations | 001 | 2 | NIH | 12/19/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01NS136022 | Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS (SEA-NOBI-ALS) | 000 | 1 | NIH | 10/10/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG084236 | ACTS (AD Clinical Trial Simulation): Developing Advanced Informatics Approaches for an Alzheimer's Disease Clinical Trial Simulation System | 002 | 2 | NIH | 3/8/2025 | $0 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG071513 | Investigating tau and ApoE4-mediated alterations in oligodendrocyte progenitor cells | 000 | 3 | NIH | 3/27/2025 | $0 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG071226 | Endothelial cell senescence and APOE4 in vascular cognitive impairment and dementia | 000 | 2 | NIH | 3/14/2025 | $0 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01DK117910 | Mechanisms of Hereditary Pancreatitis | 001 | 5 | NIH | 3/4/2025 | $43,194 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG084236 | ACTS (AD Clinical Trial Simulation): Developing Advanced Informatics Approaches for an Alzheimer's Disease Clinical Trial Simulation System | 001 | 2 | NIH | 1/15/2025 | $939,381 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | K23DK131338 | Approaches and Outcomes of Shared Decision-making and Patient Centered Care Delivery in Barrett's Esophagus | 002 | 3 | NIH | 12/4/2024 | $252,837 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG089380 | Bio-RaPID: Biomarkers and Rates of Progression In Dementia. | 000 | 1 | NIH | 11/21/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG054199 | APOE and microglia-mediated progression in tau pathology in AD | 000 | 3 | NIH | 12/27/2024 | $162,269 |
| | 2025 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA229560 | Role of ICAM1 in development and progression of pancreatic cancer | 000 | 5 | NIH | 11/6/2024 | $0 |
| | 2025 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U24CA277825 | The Data, Evaluation, and Coordination Center (DECC) for Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) | 000 | 3 | NIH | 11/14/2024 | $0 |
| | 2025 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R24OD035424 | Implementation of automated staining in conjunction with spatial analyses | 000 | 1 | NIH | 10/28/2024 | $0 |
| | 2025 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R24AG074867 | Tailoring Recruitment Communication using Virtual Human Technology to Increase Participation of Older Minority Adults in Clinical Trials | 002 | 4 | NIH | 2/26/2025 | $688,679 |
| | 2025 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21AG085314 | NUP50 as a modifier and risk factor for TDP-43 pathology in FTD/ALS | 000 | 1 | NIH | 11/29/2024 | $0 |
| | 2025 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | K01NS110930 | Osteopontin-CD44 role in the malignancy of lateral ventricle infiltrating glioblastoma | 000 | 5 | NIH | 2/6/2025 | $0 |
| | 2025 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R37CA248298 | Role of Sirt2 in T Cell Metabolism | 001 | 4 | NIH | 1/24/2025 | $49,114 |
| | 2025 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA229811 | Predicting Breast Cancer Risk after Benign Percutaneous Biopsy | 000 | 5 | NIH | 11/5/2024 | -$6,396 |
| | 2025 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA081436 | Protein Kinase C Signaling Mechanisms in Cancer | 000 | 25 | NIH | 11/5/2024 | -$53,444 |
| | 2025 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R56HL160643 | Characterization of TRPC6 to predict and prevent chemotherapy-related heart failure | 000 | 1 | NIH | 2/17/2025 | $0 |
| | 2025 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01DK117910 | Mechanisms of Hereditary Pancreatitis | 000 | 4 | NIH | 3/4/2025 | -$43,194 |
| | 2025 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R56HL160545 | Restoring immune-vascular axis integrity to alleviate acute lung injury in sepsis | 000 | 1 | NIH | 3/20/2025 | -$7,225 |
| | 2025 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21HL159561 | Endoscopic-mediated hydrodynamic gene therapy for hemophilia B through the biliary system | 000 | 3 | NIH | 11/25/2024 | $0 |
| | 2025 | 2021 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1AG054199 | APOE and microglia-mediated progression in tau pathology in AD | 000 | 2 | NIH | 12/27/2024 | -$162,269 |
| | 2025 | 2021 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1AG054199 | APOE and microglia-mediated progression in tau pathology in AD | 001 | 2 | NIH | 3/4/2025 | $0 |
|
